Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01623830 · ClinicalTrials.gov registry record · NA
Targeting Reconsolidation to Prevent Return of Fear
A NA study of Fear of Flying, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT01623830: Completed NA study of Fear of Flying, sponsored by Emory University.
NCT01623830 is a NA study of Fear of Flying that has completed, run by Emory University. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01623830, a NA study of Fear of Flying, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall aim of this project is to determine if using a cue to trigger (and reactivate) the fear memory 10 minutes prior to exposure treatment sessions leads to less anxiety in patients with a fear of flying. The long term goals are to establish if targeting the reconsolidation of fear with a reminder of the fear is effective for human clinical populations in reducing relapse (return of fear). In this investigation, the investigators propose to treat 64 patients diagnosed with a fear of flying (FOF) using virtual reality exposure therapy (VRE). All patients in the study will receive exactly the same exposure treatment using a virtual airplane.
Primary Outcome
a 33-item scale measuring intensity of FOF. Items are rated on a 9-point scale ranging from 0 ( not at all) to 8 ( very severely disturbing). The possible range of scores is 0-264 with higher total scores indicating greater fear of flying intensity.Test-retest reliability for 15 WL patients was .92, and it has been sensitive to change with treatment.
Conditions Studied
Interventions
- BEHAVIORAL Virtual Reality Exposure Therapy
Study Locations (1)
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-06 |
| Phase | NA |
What the finished NCT01623830 record still lists
NCT01623830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Fear of Flying appearing as the primary indexed condition, and to 1 intervention - of which Virtual Reality Exposure Therapy is the first listed.
NCT01623830 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT01623830 about?
NCT01623830 is a clinical study titled "Targeting Reconsolidation to Prevent Return of Fear". The overall aim of this project is to determine if using a cue to trigger (and reactivate) the fear memory 10 minutes prior to exposure treatment sessions leads to less anxiety in patients with a fear of flying. The long term goals are to establish if targeting the reconsolidation of fear with a rem...
What is the current status of trial NCT01623830?
This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2012-07. Estimated completion is 2016-06.
What conditions does trial NCT01623830 study?
This clinical trial studies the following conditions: Fear of Flying.
What interventions are being tested in trial NCT01623830?
The interventions under investigation include: Virtual Reality Exposure Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01623830?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01623830 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01623830's enrollment target sits among peer trials
89 972nd of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia